Cellectis
FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally.
- Country
- France
- Ticker
- CLLS
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| CAR-T cell therapy | therapeutics-platforms | Low | → |
| Personalized & regenerative medicine | regenerative-personalized | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.